<?xml version="1.0"?>
<presentation title="07 Shanyu Qin" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2010" type="compound" hasExternalAudio="0" uid="{315D1622-408A-44AB-A0C3-DE05A398C304}">
	<presenters>
		<presenter name="Shanyu Qin" title="China" email="" web="" phone="" photoAssetId="">
			<bio>EUS-guided ethanol injection therapy of
pancreatic solid tumor</bio>
		</presenter>
	</presenters>
	<references/>
	<soundAssets>
		<soundAsset id="sndAsset0" src="sound1.mp3" embedded="0" size="266285" duration="9510"/>
		<soundAsset id="sndAsset1" src="sound2.mp3" embedded="0" size="756342" duration="27012"/>
		<soundAsset id="sndAsset2" src="sound3.mp3" embedded="0" size="299931" duration="10711"/>
		<soundAsset id="sndAsset3" src="sound4.mp3" embedded="0" size="822171" duration="29363"/>
		<soundAsset id="sndAsset4" src="sound5.mp3" embedded="0" size="1117668" duration="39916"/>
		<soundAsset id="sndAsset5" src="sound6.mp3" embedded="0" size="235565" duration="8413"/>
		<soundAsset id="sndAsset6" src="sound7.mp3" embedded="0" size="232639" duration="8308"/>
		<soundAsset id="sndAsset7" src="sound8.mp3" embedded="0" size="956754" duration="34169"/>
		<soundAsset id="sndAsset8" src="sound9.mp3" embedded="0" size="939199" duration="33542"/>
		<soundAsset id="sndAsset9" src="sound10.mp3" embedded="0" size="1397074" duration="49895"/>
		<soundAsset id="sndAsset10" src="sound11.mp3" embedded="0" size="740982" duration="26463"/>
		<soundAsset id="sndAsset11" src="sound12.mp3" embedded="0" size="1656731" duration="59168"/>
		<soundAsset id="sndAsset12" src="sound13.mp3" embedded="0" size="1101576" duration="39342"/>
		<soundAsset id="sndAsset13" src="sound14.mp3" embedded="0" size="1440959" duration="51462"/>
		<soundAsset id="sndAsset14" src="sound15.mp3" embedded="0" size="2167999" duration="77428"/>
		<soundAsset id="sndAsset15" src="sound16.mp3" embedded="0" size="1256639" duration="44879"/>
		<soundAsset id="sndAsset16" src="sound17.mp3" embedded="0" size="284571" duration="10163"/>
		<soundAsset id="sndAsset17" src="sound18.mp3" embedded="0" size="198994" duration="7106"/>
		<soundAsset id="sndAsset18" src="sound19.mp3" embedded="0" size="770239" duration="27508"/>
		<soundAsset id="sndAsset19" src="sound20.mp3" embedded="0" size="363565" duration="12984"/>
		<soundAsset id="sndAsset20" src="sound21.mp3" embedded="0" size="288228" duration="10293"/>
		<soundAsset id="sndAsset21" src="sound22.mp3" embedded="0" size="677348" duration="24191"/>
		<soundAsset id="sndAsset22" src="sound23.mp3" embedded="0" size="182171" duration="6506"/>
		<soundAsset id="sndAsset23" src="sound24.mp3" embedded="0" size="326994" duration="11678"/>
		<soundAsset id="sndAsset24" src="sound25.mp3" embedded="0" size="322605" duration="11521"/>
		<soundAsset id="sndAsset25" src="sound26.mp3" embedded="0" size="308708" duration="11025"/>
		<soundAsset id="sndAsset26" src="sound27.mp3" embedded="0" size="517165" duration="18470"/>
		<soundAsset id="sndAsset27" src="sound28.mp3" embedded="0" size="234834" duration="8386"/>
		<soundAsset id="sndAsset28" src="sound29.mp3" embedded="0" size="250925" duration="8961"/>
		<soundAsset id="sndAsset29" src="sound30.mp3" embedded="0" size="1023314" duration="36546"/>
		<soundAsset id="sndAsset30" src="sound31.mp3" embedded="0" size="56365" duration="2013"/>
	</soundAssets>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
	</graphicAssets>
	<backgroundSound soundAssetId="" looping="0" volume="1.0000000"/>
	<narration>
		<audioTracks>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset0">
				<startTimestamp slideIndex="0" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="0" stepIndex="0" timeOffset="9.4759998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset1">
				<startTimestamp slideIndex="1" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="1" stepIndex="0" timeOffset="26.9599991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset2">
				<startTimestamp slideIndex="2" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="2" stepIndex="0" timeOffset="10.6770000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset3">
				<startTimestamp slideIndex="3" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="3" stepIndex="0" timeOffset="29.3290000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset4">
				<startTimestamp slideIndex="4" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="4" stepIndex="0" timeOffset="39.8699989"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset5">
				<startTimestamp slideIndex="5" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="5" stepIndex="0" timeOffset="8.3750000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset6">
				<startTimestamp slideIndex="6" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="6" stepIndex="0" timeOffset="8.2749996"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset7">
				<startTimestamp slideIndex="7" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="7" stepIndex="0" timeOffset="34.1300000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset8">
				<startTimestamp slideIndex="8" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="8" stepIndex="0" timeOffset="33.5000000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset9">
				<startTimestamp slideIndex="9" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="9" stepIndex="0" timeOffset="49.8499985"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset10">
				<startTimestamp slideIndex="10" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="10" stepIndex="0" timeOffset="26.4260000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset11">
				<startTimestamp slideIndex="11" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="11" stepIndex="0" timeOffset="59.1259995"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset12">
				<startTimestamp slideIndex="12" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="12" stepIndex="0" timeOffset="39.3059998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset13">
				<startTimestamp slideIndex="13" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="13" stepIndex="0" timeOffset="51.4179993"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset14">
				<startTimestamp slideIndex="14" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="14" stepIndex="0" timeOffset="77.3769989"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset15">
				<startTimestamp slideIndex="15" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="15" stepIndex="0" timeOffset="44.8450000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset16">
				<startTimestamp slideIndex="16" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="16" stepIndex="0" timeOffset="10.1099997"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset17">
				<startTimestamp slideIndex="17" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="17" stepIndex="0" timeOffset="7.0739999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset18">
				<startTimestamp slideIndex="18" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="18" stepIndex="0" timeOffset="27.4610000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset19">
				<startTimestamp slideIndex="19" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="19" stepIndex="0" timeOffset="12.9460000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset20">
				<startTimestamp slideIndex="20" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="20" stepIndex="0" timeOffset="10.2440000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset21">
				<startTimestamp slideIndex="21" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="21" stepIndex="0" timeOffset="24.1570000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset22">
				<startTimestamp slideIndex="22" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="22" stepIndex="0" timeOffset="6.4699998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset23">
				<startTimestamp slideIndex="23" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="23" stepIndex="0" timeOffset="11.6450000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset24">
				<startTimestamp slideIndex="24" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="24" stepIndex="0" timeOffset="11.4779997"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset25">
				<startTimestamp slideIndex="25" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="25" stepIndex="0" timeOffset="10.9779997"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset26">
				<startTimestamp slideIndex="26" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="26" stepIndex="0" timeOffset="18.4180000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset27">
				<startTimestamp slideIndex="27" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="27" stepIndex="0" timeOffset="8.3420000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset28">
				<startTimestamp slideIndex="28" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="28" stepIndex="0" timeOffset="8.9090000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset29">
				<startTimestamp slideIndex="29" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="29" stepIndex="0" timeOffset="36.5000000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset30">
				<startTimestamp slideIndex="30" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="30" stepIndex="0" timeOffset="1.9690000"/>
			</audioTrack>
		</audioTracks>
	</narration>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>true</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>true</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="true"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>true</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>true</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>true</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>true</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="always"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="EUS-guided ethanol injection therapy (EUS-EI) of pancreatic solid tumor" titleNormalized="eus-guided ethanol injection therapy (eus-ei) of pancreatic solid tumor" src="slide1.swf" size="1292" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="9.4749998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS-guided ethanol injection therapy (EUS-EI) of pancreatic solid tumor
Shanyu Qin

Department of Gastroenterology,First Affiliated Hospital of Guangxi Medical University</text>
		</slide>
		<slide index="1" title="Neuroendocrine tumors (NETs)" titleNormalized="neuroendocrine tumors (nets)" src="slide2.swf" size="1915" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="26.9589991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>a rare type of neoplasms with high heterogeneity incidence of 3.56/100,000 and constantly increased originating from the diffuse neuroendocrine system, and classified into neuroendocrine tumors(NETs) and neuroendocrine cancers occur in multiple organs and tissues of the human body (gastrointestinal tract, pancreas, liver, gallbladder, bile duct,bronchial tube, lung, thyroid gland, parathyroid gland, adrenal medullary, accessory ganglion and neuroendocrine cells from other parts of the body)
 Gastrointestinal, pancreatic of neuroendocrine tumors are the most common types, and account for 55%-70% of all NETs.
Fraenkel M, et al. Front Horm Res 2015;44: 1-23 
Yao JC,et al. Clin Oncol 2008;26: 3063-3072
Neuroendocrine tumors (NETs)</text>
		</slide>
		<slide index="2" title="NENs summary" titleNormalized="nens summary" src="slide3.swf" size="91765" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.6790003"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Arvind Dasari, et al. JAMA Oncol..2017.5:89
US SEER（Surveillance, Epidemiology, and End Results ）data showed that the overall incidence of NETs has increased rapidly compared to malignant tumors.
NENs summary</text>
		</slide>
		<slide index="3" title="Clinical presentation" titleNormalized="clinical presentation" src="slide4.swf" size="2128" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="29.3280005"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Clinical presentation
 Clinical presentation of NETs are diverse and non-specific.
 NETs can be divided into functional and non-functional NETs according to whether it has hormone secretion function and clinical symptoms caused by these hormones or not.
  Clinical symptoms caused by functional NETs are related to secreted bioactive substances, such as gastrin tumor, insulinoma, glucagon tumor, VIP, somatostatin tumor, pancreatic polypeptide tumor.
 The main presentation of non-functional NETs are non-specific symptoms caused by tumor itself.</text>
		</slide>
		<slide index="4" title="Insulinoma (functional NET)" titleNormalized="insulinoma (functional net)" src="slide5.swf" size="4302" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="39.8689989"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>The incidence of insulinoma has been increased by years.92% of the insulinomas are benign tumors, 90% are single and less than 2cm in diameter. Malignant insulinomas are usually larger than 3cm in diameter. 
 Surgical resection including laparotomy and laparoscopy remains the golden standard treatment for insulinoma. However, the incidence of post-operation complications is high. For instance, pancreatic fistula incidence is 32.2% . Even with DVSS, the post-operation incidence of Grade A pancreatic fistula is 70% and 28% for Grade B pancreatic fistula.
 EUS-FNI is a minimal invasive treatment which has been used in insulinoma and achieved a good therapeutic effect.


Zhao YP, et al. Surgical management of patients with insulinomas:Result of 292 cases in a single institution[J].Journal of surgical oncology.2011,103(2):169-174.
 Jürgensen C, Schuppan D, Neser F, et al. EUS-guided alcohol ablation of an insulinoma [J]. Gastrointestinal endoscopy. 2006, 63(7):1059-1062.
Qin SY,et al. EUS-guided ethanol ablation of insulinomas: case series and literature review [J]. Medicine (Baltimore). 2014, 93(14):e85.
韩显林 赵玉沛，等。达芬奇机器人手术系统联合术中超声定位对胰岛素瘤 精50例精准切除50例经验总结。中华外科杂志。2016.54（1）:30-33
Insulinoma (functional NET)</text>
		</slide>
		<slide index="5" title="EUS images for 24/41 patients" titleNormalized="eus images for 24/41 patients" src="slide6.swf" size="312620" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.3790001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS images for 24/41 patients
Case 1
10mm×7.5mm
Case 2
4mm×3mm
Case 3
11mm×10mm
Case 4
11mm×9mm
Case 5
20mm×15mm
Case 6
8mm×6mm
Case 7
13mm×10mm
Case 8
27mm×26mm
Case 9
10mm×8mm
Case 10
11mm×10mm
Case 11
9mm×8mm
Case 12
14mm×13mm
Case 13
13.6mm×13mm
Case 14
16mm×15mm
Case 15
27mm×15mm
Case 16
13mm×10mm
Case 18
19.1mm×17.2mm
Case 17
1.0mm×10mm
Case 20
19mm×16.9mm
Case 19
0.99mm×0.67mm
Case 21
8.2mm×9.1mm
Case 22
9.9mm×16.3mm
Case 23
9.2mm×8.7mm;
10mm×8.7mm
Case 24
7.7mmx8.9mm</text>
		</slide>
		<slide index="6" title="Table1 Clinical characteristics of insulinoma patients" titleNormalized="table1 clinical characteristics of insulinoma patients" src="slide7.swf" size="4111" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.2739996"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>case
gender
 age 
course of the disease 
 tumor diameter
case（n）
case（n）
single tumor 
 multiple tumors 
 tumor location（n） 
 tumor location（n） 
 tumor location（n） 
(male/female)
(years old) 
 (months)
（cm）
 ＜1cm
＞1cm
（n）
（n）
 head
 body
 tail
EUS-FNI
41
9\2
45.24±10.87 
28.84±30.51
1.39±0.61
9
32
35
6
14
9
8
 
Table1 Clinical characteristics of insulinoma patients</text>
		</slide>
		<slide index="7" title="Insulinoma" titleNormalized="insulinoma" src="slide8.swf" size="1606" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="34.1290011"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>41 patients were treated by EUS-EI successfully and had no major complications. The diameter of insulinoma played a vital role in theraputic decision.
 The patients were divided into two groups: in Group A (9 patients), the tumor diameter was less than 1cm while in Group B (32 patients) the diameter was larger than 1cm. Differences in diagnosis and treatment were compared.
 
Insulinoma</text>
		</slide>
		<slide index="8" title="Diagnosis(CT)" titleNormalized="diagnosis(ct)" src="slide9.swf" size="1898" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="33.4990000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Diagnosis(CT)
 ≤1cm（9 cases）


CT: 2 cases were diagnosed with pancreatic mass by abdomenal CT




 ＞1cm(32 cases)


CT: 25 cases were diagnosed with pancreatic mass by abdomenal CT
According to previous studies, the diagnostic yield of CT is 85%, and the rate could be increased by combining EUS with CT.
Han JF,Zhan F,Bao YQ,et al .Chin Med J,2011,124(3):476-479</text>
		</slide>
		<slide index="9" title="Diagnosis(EUS and EUS-FNA)" titleNormalized="diagnosis(eus and eus-fna)" src="slide10.swf" size="2376" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="49.8489985"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Diagnosis(EUS and EUS-FNA)
 ≤1cm

EUS:All cases showed a hypoechoic mass with a clear border.


CE-EUS:hyper-enhanced before operation

EUS-FNA:9 cases of cytological smears, 3 cases of cell block in 9cases

 &gt;1cm

EUS:Among the 32 cases, all with a clear border, 2 were hyperechoic, 29 were hypoechoic and 1 were isoechoic. 

CE-EUS: hyper-enhanced before operation 

EUS-FNA:32 cases of cytological smears, 25 cases of cell block in 32cases 
 

Reports found that EUS as well as EUS-FNA was the most sensitive modality to diagnose pancreatic mass with a sensitivity of 93%.

Patel S,Narwari M,Parekh D,et al.Insulinoma:case report and review diagnostic
 and treatment modalities.Assoc Physicians India,2013,61(6):423-426</text>
		</slide>
		<slide index="10" title="CE-EUS" titleNormalized="ce-eus" src="slide11.swf" size="215057" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="26.4290003"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>CE-EUS
EUS：hyperechoic CE-EUS：hyper-enhanced
EUS：isoechoic CE-EUS: hyper-enhanced
EUS：hypoechoic CE-EUS:hyper-enhanced</text>
		</slide>
		<slide index="11" title="injection" titleNormalized="injection" src="slide12.swf" size="2220" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="59.1249995"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>injection
 &lt;1cm
1.The needle was punctured into the tumor center, ethanol was injected slowly until white smog permeated to the tumor border. Held the needle for 5 seconds before withdrawing it quickly in case the leakage of ethanol would cause GI ulcer.
 &gt;1cm
The needle was punctured near to the distal tumor border. Ethanol was injected into the tumor slowly while retreating the needle to the proximal border before withdrawing quickly out of the tumor.
Due to the large size of the tumor, injection with multiple points like sector was adopted if necessary in order to damage the tumor completely
The permeated shape of the ethanol during injection should be monitored closely in case of leakage.</text>
		</slide>
		<slide index="12" title="injection volume" titleNormalized="injection volume" src="slide13.swf" size="155927" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="39.3049998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>injection volume
 &lt;1cm

1.The injection volume was equal to the diameter
 &gt;1cm

1.The injection volume for round and oval insulinoma was in accordance with its volume (4/3∏R2)
2.The injection volume should be decreased if the tumor was near to pancreatic duct or vascular.
3D CT show its volume</text>
		</slide>
		<slide index="13" title="treatment times" titleNormalized="treatment times" src="slide14.swf" size="2109" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="51.4169993"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>treatment times
 &lt;1cm
1.The tumor of the 9 cases was damaged completely with only one treatment and the patient got relieved. No recurrence was found during the follow-up.



 &gt;1cm
1.The tumor was near pancreatic duct in 2 cases, and 13 cases were close to vascular. 32 patients were treated 42 times in total in order to prevent complications.
2.Patients were treated by several times and each time with only a small amount of injection. No complications occurred.
3. If there's no relief after single injection, repeated treatment could be carried out even in a short time.
4. Recurrence of 3patients was found during the follow-up.


</text>
		</slide>
		<slide index="14" title="CE-EUS" titleNormalized="ce-eus" src="slide15.swf" size="2225" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="77.3759989"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>CE-EUS
 &lt;1cm
1.The tumor was hyperenhanced before the treatment and hypoenhanced after treatment.
2. CE-EUS should be carried out after the injetcion was finished in order to see if there's need to repeat the injection.
 &gt;1cm
 1.The tumor was hyperenhanced before the treatment and hypoenhanced after treatment. The tumor should be damaged completely till there's no blood supply.
 2.CE-EUS should be carried out after the injetcion was finished, if there's image of hyperenhanced lesion, ethanol should be injected till the entire tumor turned out to be with no blood supply. 
3.There could be blood supply to the tumor border after completely damage, but there should not be blood supply in the tumor. 
4.CE-EUS should be monitor during the follow-up.</text>
		</slide>
		<slide index="15" title="BG" titleNormalized="bg" src="slide16.swf" size="18748" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="44.8440012"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>BG
 &lt;1cm
1.The tumor was small and the BG of the patient went back to normal 6 hours after the injection when they started to eat.

 &gt;1cm
 1.The tumor was large. 12 patients showed no obvious changes in BG 1 hour after the treatment and an increase trend after 6 hours. However their BG level at 0am, 3am or 6am could be still more than 3mmol/L.（
 2.When the BG was lower than 3mmol/L, treatment should be repeated till it went back to normal.
 Most patients showed hypoglycemic symoptoms at 0am, 3am or 6am while their BG level was normal during other time. Among the patients, BG of 2 patients were 3mmol/L while others were lower than 3mmol/L. After successful treatment, their BG increased to more than 3mmol/L and showed no hypoglycemia.</text>
		</slide>
		<slide index="16" title="insulin" titleNormalized="insulin" src="slide17.swf" size="20454" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.1089997"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>insulin
 &lt;1cm
 &gt;1cm

No matter how large the tumor is, the insulin level would decrease after treatment. The trend would not be obvious if there's no complete cure.
</text>
		</slide>
		<slide index="17" title="C-peptide" titleNormalized="c-peptide" src="slide18.swf" size="21529" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="7.0729999"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>C-peptide
 &lt;1cm
 &gt;1cm

No matter how large the tumor is, the C-peptide level would decrease after treatment. The trend would not be obvious if there's no complete cure.</text>
		</slide>
		<slide index="18" title="CgA" titleNormalized="cga" src="slide19.swf" size="11240" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="27.4600004"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>CgA
 &lt;1cm
 &gt;1cm

 Previous study showed that CgA is a reliable serum diagnostic biomarker for NETs except for insulinoma. We also carried out an experiment and found that the CgA level changes after the treatment compared to that before the treatment no matter how large the tumor was, however, no statistical significance was found.
 Rindi G, Wiedenmann B. Endocrinol 2012, 8(1):54–64.
Qiao XW, Qiu , Yuan-Jia et al. Endocrine Disorders 2014, 14:64
CgA level before and after treament: The median was 56.34 ng/mL （19.96±247.31 ng/mL ). There's no statistical difference.</text>
		</slide>
		<slide index="19" title="complications" titleNormalized="complications" src="slide20.swf" size="1925" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="12.9450001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>complications
 &lt;1cm









 


&gt;1cm




 One patient's serum amylase level increased a little bit after the treatment and went back to normal soon. No major complications were found after the treatment.</text>
		</slide>
		<slide index="20" title="follow-up" titleNormalized="follow-up" src="slide21.swf" size="2718" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.2430004"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>follow-up
 &lt;1cm
1.CT:The tumor shrinked after the treatment. There's no necrosis.
2.EUS:The tumor was hyperechoic 3 days after the treatment and then turned to hypoechoic image.
3.The tumor shrinked 1 month after the treatment and disappeared after year.
4.3 patients pancreatic mass disappear 1year after the treatmeat.
 &gt;1cm

1.CT:There's necrosis 1 month after the treatment and it could last for a year.
2.EUS:The tumor was hyperechoic 3 days after the treatment and then turned to hypoechoic image.
3.The tumor shrinked 1 month after the treatment. And the longer the time was, the more it shrinked.

 All patients were follow up by CE-EUS.CE-EUS images show hyperenhancing pancreatic mass before operation and hypeonhancing pancreatic mass after operation.</text>
		</slide>
		<slide index="21" title="follow up by CE-EUS" titleNormalized="follow up by ce-eus" src="slide22.swf" size="349693" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="24.1589998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>follow up by CE-EUS
before operation
3 month after operation
2 year after operation
6month after operation
1month after operation</text>
		</slide>
		<slide index="22" title="follow up by EUS" titleNormalized="follow up by eus" src="slide23.swf" size="273210" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="6.4689998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>follow up by EUS
bofore operation
hypoecho
3days after operation
hyperecho
1month after operation
hypoecho
3month after operation
hypoecho
6month after operation
hypoecho
12month er operation
hypoecho</text>
		</slide>
		<slide index="23" title="follow up by CT" titleNormalized="follow up by ct" src="slide24.swf" size="150122" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.6489996"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>follow up by CT
before operation
1month after operation
after operation
3month after operation
6month afteroperation</text>
		</slide>
		<slide index="24" title="Multiple neuroendocrine neoplasms type-1 (MEN-1)" titleNormalized="multiple neuroendocrine neoplasms type-1 (men-1)" src="slide25.swf" size="2325" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.4769997"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Multiple neuroendocrine neoplasms type-1 (MEN-1)
 A type of familial tumor syndrome with autosomal dominant genetic disorder, with an incidence of 1/3 to 1/50,000 involves parathyroid gland, pancreas, gastrointestinal tract, adrenal gland, pituitary gland and other systems or organs, and causes neoplastic diseases such as parathyroid adenoma and insulinoma .
 5% of the insulinomas are related to MEN-1. 
 3 patients were treated in our study. 
Oberg K.Neuroendocrine tumors (NETs): historical overview and epidemiology［J］.Tumori，2010，96(5)：797-801.
Garcia-Carbonero P. JImenez-Fonseca，et al.SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) .Clin Transl Oncol (2014) 16:1025–1034.</text>
		</slide>
		<slide index="25" title="Pre-operation female, 36y,chief complaint &quot;repeated fatigue for more than 1 year and repeated syncope for more than 5 months&quot;" titleNormalized="pre-operation female, 36y,chief complaint &quot;repeated fatigue for more than 1 year and repeated syncope for more than 5 months&quot;" src="slide26.swf" size="337208" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.9769997"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Pre-operation female, 36y,chief complaint "repeated fatigue for more than 1 year and repeated syncope for more than 5 months"
IHC：CgA(+),Syn(+),NSE(-），Insulin(-),CK8/18(-),Ki67 1%(+)
CT
EUS
elastography
CE-EUS</text>
		</slide>
		<slide index="26" title="NF-PNENs" titleNormalized="nf-pnens" src="slide27.swf" size="2881" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="18.4190001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>The immune responses of non-functional pancreatic neuroendocrine neoplasms(NF-pNENs) both in blood and tissue also showed an elevated hormone level. However, concentration was not sufficient to induce symptoms. The concentration was not sufficient to induce symptoms.
 The traditional treatment for NF-pNENs was surgery.
 The updated guidelines for NF- pNENs in 2016 suggested that NF-NENs less than 2cm could be followed up.
 4 patients were treated in our study. 

	NF-PNENs</text>
		</slide>
		<slide index="27" title="NF-PENT female, 25y，no symptom，diagnosed by health check" titleNormalized="nf-pent female, 25y，no symptom，diagnosed by health check" src="slide28.swf" size="355585" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.3410000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>NF-PENT female, 25y，no symptom，diagnosed by health check 
Ki67:1%</text>
		</slide>
		<slide index="28" title="CH-EUS before and after treatment" titleNormalized="ch-eus before and after treatment" src="slide29.swf" size="194118" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.9080004"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>CH-EUS before and after treatment
Pre-operation:cotrast-enhance EUS showing intense uptake of the conast in the arterial phase 
1st CH-EUS after operation
 2nd CH-EUS after operation</text>
		</slide>
		<slide index="29" title="conclusion" titleNormalized="conclusion" src="slide30.swf" size="1580" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="36.4990000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>conclusion
1.pNENs can be successfully treated by EUS-EI.The therapy could improve hypoglycemic sympotoms by increasing FBG and decreasing serum insulin and C-peptide.
2.Treatment and follow-up scheme should be decided according to the tumor size in order to improve personalized treatment.
3.CE-EUS is a useful tool in diagnosis ,treatment and follow up to pNETs.</text>
		</slide>
		<slide index="30" title="Thank your attention!" titleNormalized="thank your attention!" src="slide31.swf" size="1018" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="1.9690000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Thank your attention!</text>
		</slide>
	</slides>
</presentation>
